Literature DB >> 10393407

What is the cost of admitting patients with transient ischaemic attacks to hospital?

G Gubitz1, S Phillips, V Dwyer.   

Abstract

Financial constraints at our institution prompted us to evaluate the management of patients referred to the Acute Stroke Service because of transient ischaemic attack (TIA). We analysed age, gender, length of stay, hospital costs, discharge disposition and stroke recurrence for all cases of TIA admitted to the Acute Stroke Service between January 1, 1994, and December 31, 1996. During this time, 110 cases of TIA were admitted. All had a CT head scan, 60% had carotid Doppler ultrasound, and 30% had transthoracic echocardiography. No patients admitted with TIA died, and 92% were discharged home. The average annual cost of in-patient management of TIA was 328,000 Canadian dollars, of which 95% were accounted for by the cost of the hospital bed alone. If hospitalisation of patients with TIA could be reduced, significant cost-savings could be realised.

Entities:  

Mesh:

Year:  1999        PMID: 10393407     DOI: 10.1159/000015957

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  4 in total

1.  Management and outcomes of transient ischemic attacks in Ontario.

Authors:  David J Gladstone; Moira K Kapral; Jiming Fang; Andreas Laupacis; Jack V Tu
Journal:  CMAJ       Date:  2004-03-30       Impact factor: 8.262

2.  Description and evaluation of an acute stroke unit.

Authors:  Stephen J Phillips; Gail A Eskes; Gordon J Gubitz
Journal:  CMAJ       Date:  2002-09-17       Impact factor: 8.262

3.  Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services.

Authors:  A J Coull; J K Lovett; P M Rothwell
Journal:  BMJ       Date:  2004-01-26

4.  Cost of managing complications resulting from type 2 diabetes mellitus in Canada.

Authors:  Judith A O'Brien; Amanda R Patrick; J Jaime Caro
Journal:  BMC Health Serv Res       Date:  2003-03-21       Impact factor: 2.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.